Incidence of late stent thrombosis with bare-metal, sirolimus, and paclitaxel stents

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Stent thrombosis has become a major concern for interventional cardiology. Although infrequent, it is associated with significant morbidity and mortality. Recent attention has focused on the frequency of this complication with drug-eluting stents compared with bare-metal stents in regard to the timing (early, late, or very late) of the event, underlying mechanisms involved, and preventive strategies. Although dual antiplatelet therapy (aspirin plus thienopyridine) is crucial in mitigating the problem, there are significant issues with this management strategy, including the duration of dual antiplatelet treatment, patient compliance, variability in individual response to therapy, bleeding risk, and management of subsequent noncardiac surgical procedures. Newer strategies being evaluated to enhance the safety of drug-eluting stents include different alloys and stent designs, revisions in the polymer or drug utilized, and, ultimately, bioabsorbable platforms.

Original languageEnglish (US)
JournalReviews in Cardiovascular Medicine
Volume8
Issue numberSUPPL. 1
StatePublished - Mar 30 2007

Fingerprint

Sirolimus
Paclitaxel
Stents
Thrombosis
Drug-Eluting Stents
Metals
Incidence
Risk Management
Patient Compliance
Cardiology
Aspirin
Polymers
Hemorrhage
Morbidity
Safety
Mortality
Therapeutics
Pharmaceutical Preparations

Keywords

  • Antiplatelet therapy
  • Bare-metal stents
  • Drug-eluting stents
  • Interventional cardiology
  • Stent thrombosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Incidence of late stent thrombosis with bare-metal, sirolimus, and paclitaxel stents. / Holmes, David.

In: Reviews in Cardiovascular Medicine, Vol. 8, No. SUPPL. 1, 30.03.2007.

Research output: Contribution to journalReview article

@article{7d862b0313c74d0fb52d324bb41bc864,
title = "Incidence of late stent thrombosis with bare-metal, sirolimus, and paclitaxel stents",
abstract = "Stent thrombosis has become a major concern for interventional cardiology. Although infrequent, it is associated with significant morbidity and mortality. Recent attention has focused on the frequency of this complication with drug-eluting stents compared with bare-metal stents in regard to the timing (early, late, or very late) of the event, underlying mechanisms involved, and preventive strategies. Although dual antiplatelet therapy (aspirin plus thienopyridine) is crucial in mitigating the problem, there are significant issues with this management strategy, including the duration of dual antiplatelet treatment, patient compliance, variability in individual response to therapy, bleeding risk, and management of subsequent noncardiac surgical procedures. Newer strategies being evaluated to enhance the safety of drug-eluting stents include different alloys and stent designs, revisions in the polymer or drug utilized, and, ultimately, bioabsorbable platforms.",
keywords = "Antiplatelet therapy, Bare-metal stents, Drug-eluting stents, Interventional cardiology, Stent thrombosis",
author = "David Holmes",
year = "2007",
month = "3",
day = "30",
language = "English (US)",
volume = "8",
journal = "Reviews in Cardiovascular Medicine",
issn = "1530-6550",
publisher = "MedReviews LLC",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Incidence of late stent thrombosis with bare-metal, sirolimus, and paclitaxel stents

AU - Holmes, David

PY - 2007/3/30

Y1 - 2007/3/30

N2 - Stent thrombosis has become a major concern for interventional cardiology. Although infrequent, it is associated with significant morbidity and mortality. Recent attention has focused on the frequency of this complication with drug-eluting stents compared with bare-metal stents in regard to the timing (early, late, or very late) of the event, underlying mechanisms involved, and preventive strategies. Although dual antiplatelet therapy (aspirin plus thienopyridine) is crucial in mitigating the problem, there are significant issues with this management strategy, including the duration of dual antiplatelet treatment, patient compliance, variability in individual response to therapy, bleeding risk, and management of subsequent noncardiac surgical procedures. Newer strategies being evaluated to enhance the safety of drug-eluting stents include different alloys and stent designs, revisions in the polymer or drug utilized, and, ultimately, bioabsorbable platforms.

AB - Stent thrombosis has become a major concern for interventional cardiology. Although infrequent, it is associated with significant morbidity and mortality. Recent attention has focused on the frequency of this complication with drug-eluting stents compared with bare-metal stents in regard to the timing (early, late, or very late) of the event, underlying mechanisms involved, and preventive strategies. Although dual antiplatelet therapy (aspirin plus thienopyridine) is crucial in mitigating the problem, there are significant issues with this management strategy, including the duration of dual antiplatelet treatment, patient compliance, variability in individual response to therapy, bleeding risk, and management of subsequent noncardiac surgical procedures. Newer strategies being evaluated to enhance the safety of drug-eluting stents include different alloys and stent designs, revisions in the polymer or drug utilized, and, ultimately, bioabsorbable platforms.

KW - Antiplatelet therapy

KW - Bare-metal stents

KW - Drug-eluting stents

KW - Interventional cardiology

KW - Stent thrombosis

UR - http://www.scopus.com/inward/record.url?scp=33947611609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947611609&partnerID=8YFLogxK

M3 - Review article

C2 - 17401306

AN - SCOPUS:33947611609

VL - 8

JO - Reviews in Cardiovascular Medicine

JF - Reviews in Cardiovascular Medicine

SN - 1530-6550

IS - SUPPL. 1

ER -